Robert M. Califf
About
Robert M. Califf is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Robert M. Califf has authored 310 papers receiving a total of 30.5k indexed citations (citations by other indexed papers that have themselves been cited), including 261 papers in Cardiology and Cardiovascular Medicine, 109 papers in Surgery and 84 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Robert M. Califf's work include Acute Myocardial Infarction Research (148 papers), Cardiac Imaging and Diagnostics (84 papers) and Coronary Interventions and Diagnostics (77 papers). Robert M. Califf is often cited by papers focused on Acute Myocardial Infarction Research (148 papers), Cardiac Imaging and Diagnostics (84 papers) and Coronary Interventions and Diagnostics (77 papers). Robert M. Califf collaborates with scholars based in United States, Canada and United Kingdom. Robert M. Califf's co-authors include Eric J. Topol, David B. Pryor, Kenneth W. Mahaffey, Manesh R. Patel, Keith A.A. Fox, Jonathan P. Piccini, Kerry L. Lee, Christopher C. Nessel, Daniel E. Singer and Graeme J. Hankey and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.
In The Last Decade
Robert M. Califf
307 papers receiving 29.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Robert M. Califf United States | 90 | 24.1k | 7.8k | 6.4k | 6.0k | 2.9k | 310 | 30.5k | ||
| Frans Van de Werf Belgium | 97 | 29.8k 1.2× | 11.9k 1.5× | 4.1k 0.6× | 9.8k 1.6× | 2.6k 0.9× | 779 | 38.8k | ||
| Maarten L. Simoons Netherlands | 77 | 22.8k 0.9× | 9.8k 1.3× | 2.5k 0.4× | 8.8k 1.5× | 2.9k 1.0× | 355 | 29.8k | ||
| Carolyn H. McCabe United States | 80 | 29.7k 1.2× | 17.3k 2.2× | 5.1k 0.8× | 9.7k 1.6× | 3.0k 1.0× | 182 | 38.6k | ||
| Manesh R. Patel United States | 79 | 22.4k 0.9× | 9.4k 1.2× | 6.5k 1.0× | 8.9k 1.5× | 3.1k 1.0× | 545 | 30.9k | ||
| Paul W. Armstrong Canada | 93 | 27.5k 1.1× | 9.6k 1.2× | 2.3k 0.4× | 7.7k 1.3× | 2.3k 0.8× | 850 | 38.3k | ||
| Andrzej Budaj Poland | 56 | 19.1k 0.8× | 7.9k 1.0× | 3.4k 0.5× | 3.3k 0.5× | 1.8k 0.6× | 228 | 26.9k | ||
| Jeffrey L. Anderson United States | 91 | 20.7k 0.9× | 8.4k 1.1× | 1.9k 0.3× | 4.6k 0.8× | 5.5k 1.9× | 527 | 36.8k | ||
| Nanette K. Wenger United States | 75 | 20.5k 0.9× | 10.3k 1.3× | 1.9k 0.3× | 5.8k 1.0× | 2.1k 0.7× | 372 | 35.9k | ||
| Debabrata Mukherjee United States | 61 | 21.0k 0.9× | 11.6k 1.5× | 3.1k 0.5× | 6.6k 1.1× | 2.0k 0.7× | 466 | 29.8k | ||
| Robert J. Goldberg United States | 89 | 19.0k 0.8× | 6.1k 0.8× | 2.8k 0.4× | 3.9k 0.6× | 2.7k 0.9× | 523 | 30.6k |
Countries citing papers authored by Robert M. Califf
Since
Specialization
Citations
This map shows the geographic impact of Robert M. Califf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert M. Califf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert M. Califf more than expected).
Fields of papers citing papers by Robert M. Califf
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Robert M. Califf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert M. Califf. The network helps show where Robert M. Califf may publish in the future.
Co-authorship network of co-authors of Robert M. Califf
This figure shows the co-authorship network connecting the top 25 collaborators of Robert M. Califf. A scholar is included among the top collaborators of Robert M. Califf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert M. Califf. Robert M. Califf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Haddad, François, Nicholas Cauwenberghs, Melissa A. Daubert, et al.. (2022). Association of left ventricular diastolic function with coronary artery calcium score: A Project Baseline Health Study. Journal of cardiovascular computed tomography. 16(6). 498–508.
2.
Washam, Jeffrey B., Susanna R. Stevens, Yuliya Lokhnygina, et al.. (2015). Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). The Lancet. 385(9985). 2363–2370.
3.
Steinberg, Benjamin A., Anne S. Hellkamp, Yuliya Lokhnygina, et al.. (2014). Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. Heart Rhythm. 11(6). 925–932.
4.
Cyr, Derek D., Yuliya Lokhnygina, Richard C. Becker, et al.. (2014). OBESITY PARADOX FOR STROKE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH RIVAROXABAN AND WARFARIN IN THE ROCKET AF TRIAL. Journal of the American College of Cardiology. 63(12). A371–A371.
5.
Diepen, Sean van, Anne S. Hellkamp, Manesh R. Patel, et al.. (2013). Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation. Circulation Heart Failure. 6(4). 740–747.
6.
Piccini, Jonathan P., Susanna R. Stevens, Yuchiao Chang, et al.. (2012). Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation. Circulation. 127(2). 224–232.
7.
Halperin, Jonathan L., Zachary T. Bloomgarden, Anne S. Hellkamp, et al.. (2012). Abstract 15544: Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Subgroup Analysis of the ROCKET AF Trial. Circulation. 126.
8.
Patel, Manesh R., Kenneth W. Mahaffey, Jyotsna Garg, et al.. (2011). Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine. 365(10). 883–891.
9.
Magee, Mitchell J., John H. Alexander, Gail E. Hafley, et al.. (2008). Coronary Artery Bypass Graft Failure After On-Pump and Off-Pump Coronary Artery Bypass: Findings From PREVENT IV. The Annals of Thoracic Surgery. 85(2). 494–500.
10.
Stone, Gregg W., Robert M. Clare, Kenneth W. Mahaffey, et al.. (2006). Impact of enoxaparin on thrombus formation, coronary blood flow, and myocardial perfusion after early invasive treatment during acute coronary syndrome: Results from the SYNERGY library. Circulation. 114(18). 600–600.
11.
Whitlow, Patrick L., Alexios P. Dimas, Thomas M. Bashore, et al.. (1999). Relationship of extent of revascularization with angina at one year in the bypass angioplasty revascularization investigation (BARI). Journal of the American College of Cardiology. 34(6). 1750–1759.
12.
Brieger, David, Koon-Hou Mak, Harvey D. White, et al.. (1998). Benefit of Early Sustained Reperfusion in Patients With Prior Myocardial Infarction (The GUSTO-I Trial). The American Journal of Cardiology. 81(3). 282–287.
13.
Weaver, W. Douglas, Harvey D. White, Robert G. Wilcox, et al.. (1997). Comparisons of Characteristics and Outcomes Among Women and Men with Acute Myocardial Infarction Treated with Thrombolytic Therapy. Survey of Anesthesiology. XLI(3). 147???148–147???148.
14.
Crenshaw, Brian S., Samuel R. Ward, Christopher B. Granger, et al.. (1997). Atrial Fibrillation in the Setting of Acute Myocardial Infarction: The GUSTO-I Experience fn1fn1This study was funded by grants from Genentech, South San Francisco, California; Bayer Corporation, New York, New York; CIBA-Corning, Medfield, Massachusetts; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.. Journal of the American College of Cardiology. 30(2). 406–413.
15.
Labinaz, Marino, Michael H. Sketch, Amanda Stebbins, et al.. (1996). Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. The American Journal of Cardiology. 78(12). 1338–1344.
16.
Horrigan, M., James E. Tcheng, Robert M. Califf, et al.. (1996). Maximal benefit of integrelin platelet IIB/IIIa blockade 6–24 hours after therapy: Results of the IMPACT-II trial. Journal of the American College of Cardiology. 27(2). 55–55.
17.
Teirstein, Paul S., Steven J. Yakubov, Nancy M. Wildermann, et al.. (1996). Platelet llb/llla blockade with integrelin: Atherectomy patients. Journal of the American College of Cardiology. 27(2). 334–334.
18.
Barbagelata, Alejandro, Christopher B. Granger, Eric J. Topol, et al.. (1995). Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute Myocardial Infarction. The American Journal of Cardiology. 76(14). 1007–1013.
19.
Boehrer, James D., Stephen G. Ellis, Karen S. Pieper, et al.. (1995). Directional atherectomy versus balloon angioplasty for coronary ostial and nonostial left anterior descending coronary artery lesions: Results from a randomized multicenter trial. Journal of the American College of Cardiology. 25(6). 1380–1386.
20.
Bengtson, James R., Daniel B. Mark, Michael B. Honan, et al.. (1990). Detection of restenosis after elective percutaneous transluminal coronary angioplasty using the exercise treadmill test. The American Journal of Cardiology. 65(1). 28–34.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Frans Van de Werf Breakdown of academic impact, for papers by Maarten L. Simoons Breakdown of academic impact, for papers by Carolyn H. McCabe Breakdown of academic impact, for papers by Manesh R. Patel Breakdown of academic impact, for papers by Paul W. Armstrong Breakdown of academic impact, for papers by Andrzej Budaj Breakdown of academic impact, for papers by Jeffrey L. Anderson Breakdown of academic impact, for papers by Nanette K. Wenger Breakdown of academic impact, for papers by Debabrata Mukherjee Breakdown of academic impact, for papers by Robert J. Goldberg